Antibiotic resistance: The fate of all antibiotic monotherapies

Liz Meszaros, MDLinx

Superbugs and Superdrugs USA

Iselin, New Jersey, United States | November 13-14, 2017


Iselin, NJ, November 13, 2017--Is antibiotic resistance the fate of all antibiotic monotherapies?

According to John H. Rex, MD, FACP, chief medical officer, F2G Ltd., Manchester, UK, it is. Evolution and the lightning-fast reproductive cycles of bacteria make resistance inevitable, which have led to the current broken pipeline. The only recourse is to use the drugs available judiciously and effectively, consistently develop new ones, and to thoroughly explore and use alternatives such as vaccines and infection prevention.